OncoMatch/Clinical Trials/NCT06823167
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Is NCT06823167 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies IM-1021 for solid malignancies.
Treatment: IM-1021 — IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: all approved and available therapeutic options
Participants must have relapsed or refractory disease and have received all approved and available therapeutic options
Cannot have received: ADC with a topoisomerase-1 inhibitor payload
Exception: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload
Previously treated with an ADC with a topoisomerase-1 inhibitor payload, except: Participants with triple negative breast cancer may have received up to one prior ADC with a topoisomerase-1 inhibitor payload
Cannot have received: ROR1-targeted therapy
Previously received a ROR1-targeted therapy (eg, ADC, cell therapy, or monoclonal antibody)
Lab requirements
Blood counts
Kidney function
Liver function
Participants must have adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City Of Hope · Duarte, California
- University of California · Los Angeles, California
- Colorado Blood Cancer Institute · Denver, Colorado
- Yale University Medical Center · New Haven, Connecticut
- Tampa General Hospital · Tampa, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06823167 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior ADC with a topoisomerase-1 inhibitor payload, ROR1-targeted therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify